As the European Commission grants Marketing Authorization for the company's Ebola vaccine regimen—a key step towards enabling broader access to it for the people who need it most—we share top facts about the vaccine for the deadly virus.
One of the world's deadliest viral diseases was discovered in 1976 in Zaire, now known as the Democratic Republic of the Congo (DRC), near the Ebola River.
Since then, there have been 30 outbreaks of Ebola Virus Disease (EVD)—the worst of which hit in West Africa in 2014. During that two-year epidemic, more than 11,000 people died in Guinea, Liberia and Sierra Leone. Two in five individuals who were infected with the disease, then lost their lives.
The global health world periodically has rude awakenings that expose vulnerabilities in countries’ preparedness to handle health crises. The outbreaks of Ebola and Zika in recent years are a glaring example of this weakness, exposing how poorly prepared areas like West Africa were for threats of that magnitude. Governments, civil society, and the private sector leapt into action with the resources to help, but their aid arrived late and was not completely organized, rendering their relationships and resources underutilized.
Fortune magazine has released its latest "Change the World" list, a ranking of 57 companies that are doing well by doing good. Merck ranked second on the list for our leadership role in the fight against Ebola, including our experimental Ebola vaccine and our support for humanitarian organizations involved in Ebola relief and recovery efforts.
Join public health panel from GSK, Time, and the Center for Infectious Disease Research and Policy at the University of Minnesota as they discuss the future of tracking emerging diseases
Multimedia with summary
Just a few months after the 2015 outbreak of Ebola was contained, another virus—called Zika—commanded the public stage. It took but 14 months after Zika’s first detection in Brazil for the virus to spread through Latin America and the Caribbean to Florida. So far, the threat has gone unchecked. And to be sure, after Zika, will come another global pathogenic threat—one, that public health experts worry, may do an even better job of outsmarting and overwhelming us. The question is whether technological advances can help us turn the odds.
The Ebola Case Study: Public-Private Partnerships Deliver Relief
In response to the Ebola Epidemic in West Africa, The UPS Foundation committed $750,000 in funding and in-kind support. UPS engaged with first response agencies, providing air, ocean and ground transportation for vital relief shipments from the U.S. and Europe to West Africa.
Company Recognized for Employee Inclusion and Diversity, Overall Sustainability Efforts
DEERFIELD, Ill., March 30, 2015 /3BL Media/ – Baxter International Inc. (NYSE: BAX) is improving access to healthcare through financial and in-kind donations to address critical community needs globally. The company recently announced a public-private collaboration with Singapore’s Changi General Hospital to meet the growing demand for compounded sterile products and received recognition for organizational excellence, inclusion and diversity and corporate social responsibility efforts.
Baxter Launches Public-Private Partnership to Improve Healthcare Delivery
Almost a full year since the largest Ebola outbreak in history began, the epidemic’s death toll has passed 9,000. The greatest number of fatalities have occurred in Liberia and Sierra Leone; in recent weeks, there has been an increase in cases in Guinea. From the start of the crisis, AmeriCares has provided under-resourced hospitals and health facilities with the supplies they need to combat the outbreak, sending 43 shipments of medicine, supplies and protective equipment to partners in the three most affected countries.